Sparsentan Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 200mg, 400mg
Reference Brands: Filspari (USA)
Category: Nephrology
Sparsentan is an oral dual endothelin type A receptor (ET_A) and angiotensin II type 1 receptor (AT_1) antagonist, designed to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression. It is marketed under the brand name Filspari and available in 200 mg and 400 mg tablets. Because of its novel mechanism and risk profile (including hepatotoxicity), it is subject to a restricted drug-distribution program. Sparsentan is available in Tablets and strengths such as 200mg, 400mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Sparsentan is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Sparsentan can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Sparsentan is used to treat rare kidney diseases such as IgA nephropathy and focal segmental glomerulosclerosis (FSGS). It helps reduce proteinuria (excess protein in the urine) and slows the progression of kidney damage. Sparsentan works by blocking two key pathways involved in kidney injury — endothelin type A and angiotensin II type 1 receptors — offering dual protection to the kidneys.
Sparsentan is made from the active ingredient sparsentan, a dual-acting angiotensin II and endothelin receptor antagonist. Its chemical name is (2E)-3-[2-butyl-1-[(4′-carboxy[1,1′-biphenyl]-4-yl)methyl]-7-(2-methylpropyl)-2,6-dioxo-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-yl]-N-(2-hydroxy-2-phenylethyl)acrylamide. It is formulated with excipients such as lactose monohydrate, cellulose, and magnesium stearate depending on the dosage form.
The trade name of sparsentan is Filspári in the United States and Kinpeygo in the European Union.
Sparsentan (Filspári/Kinpeygo) is developed and marketed by Travere Therapeutics in the United States and by CSL Vifor in Europe under a licensing agreement.
The generic name of the drug is sparsentan.
The brand names of sparsentan are Filspári (USA) and Kinpeygo (EU).
Sparsentan is manufactured in the United States by Travere Therapeutics and in Europe by CSL Vifor, with global distribution to markets where treatment for IgA nephropathy and FSGS is approved.
Related Products
Doxercalciferol
Strength:
0.5 mcg, 1 mcg, 2.5mcg, 2 mcg/mL
Form: Capsules / Injection
Reference Brands: Hectorol (USA)
View Details
Cysteamine Bitartrate
Strength:
25mg,50 mg, 75mg, 150 mg
Form: Capsules / Eye Drop
Reference Brands: Cystagon (USA/EU), Procysbi(USA/EU), Cystadrops (EU/UK)
View Details
Bumetanide
Strength:
0.5 mg, 1 mg, 2 mg, 0.25 mg/mL
Form: Tablet / Injection
Reference Brands: Bumex (USA), Burinex(EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
